Financial Lp Hrt Purchases 14,556 Shares of Profusa (NASDAQ:PFSA) Stock

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt purchased 14,556 shares of Profusa stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $0.96 per share, with a total value of $13,973.76. Following the completion of the acquisition, the insider directly owned 108,301 shares of the company’s stock, valued at approximately $103,968.96. This trade represents a 15.53% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, August 4th, Financial Lp Hrt purchased 1,368 shares of Profusa stock. The stock was bought at an average cost of $0.95 per share, with a total value of $1,299.60.
• On Wednesday, July 29th, Financial Lp Hrt purchased 1,310 shares of Profusa stock. The stock was bought at an average cost of $1.01 per share, with a total value of $1,323.10.

Profusa Stock Performance

Shares of NASDAQ PFSA traded down $0.07 during trading on Wednesday, hitting $0.91. 51,493 shares of the company traded hands, compared to its average volume of 230,077. The firm has a market capitalization of $173,470.00, a price-to-earnings ratio of -0.00 and a beta of 0.52. The business’s fifty day moving average is $3.90 and its 200 day moving average is $34.82. Profusa, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1,297.50.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on PFSA shares. Wall Street Zen raised Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.